Safety
hypoxia, neutropenia, leukopenia
HYPOXIA, ADVERSE EVENT, NEUTROPENIA, LEUKOPENIA
All patients (100%) had at least one treatment-related TEAE, and 68.0% of patients had at least one grade 3–4 treatment-related TEAE. The most frequently observed treatment-related TEAEs were leukopenia (72.0%) and neutropenia (68.0%; Treatment-related TEAEs in ≥10% of all patients and all grade 3–4 treatment-related TEAEsAbbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; E7389-LF, eribulin liposomal formulation; TEAE, treatment-emergent adverse event.


Three patients (12.0%) had at least one TEAE leading to study drug discontinuation, 2 of whom were in the E7389-LF every-3-weeks cohorts (one case of hypoxia in the 2.1 mg/m